[1] |
中华医学会神经病学分会神经肌肉病学组, 中华医学会神经病学分会肌电图及临床神经电生理学组, 中华医学会神经病学分会神经免疫学组.中国吉兰-巴雷综合征诊治指南[J].中华神经科杂志, 2010, 43(8):583. doi: 10.3760/cma.j.issn.1006-7876.2010.08.018 |
[2] |
高竹风, 徐晓峰.脑出血术后合并格林-巴利综合征1例报道[J].世界最新医学信息文摘, 2018, 18(39):192. |
[3] |
吴章薇, 赵军, 李冰洁, 等.以手术为诱因的重型吉兰巴雷综合征临床特点和预后分析[J].中国神经精神疾病杂志, 2017, 43(5):300. doi: 10.3969/j.issn.1002-0152.2017.05.009 |
[4] |
KUOK CH, TSAI PS, HSU YW, et al.Postoperative delayed respiratory failure caused by Guillain-Barré syndrome--a case report[J].Acta Anaesthesiol Taiwan, 2007, 45(1):43. |
[5] |
SAHAI N, HWANG KS, EMAMI A.Guillain-Barré syndrome following elective spine surgery[J].Eur Spine J, 2017, 26(Suppl 1):6. |
[6] |
GENSICKE H, DATTA AN, DILL P, et al.Increased incidence of Guillain-Barre syndrome after surgery[J].Eur J Neurol, 2012, 19(9):1239. doi: 10.1111/j.1468-1331.2012.03730.x |
[7] |
YANG B, LIAN Y, LIU Y, et al.A retrospective analysis of possible triggers of Guillain-Barre syndrome[J].J Neuroimmunol, 2016, 293:17. doi: 10.1016/j.jneuroim.2016.02.003 |
[8] |
HOCKER S, NAGARAJAN E, RUBIN M, et al.Clinical factors associated with Guillain-Barré syndrome following surgery[J].Neurol Clin Pract, 2018, 8(3):201. doi: 10.1212/CPJ.0000000000000451 |
[9] |
段晓琴, 陈岩, 黄萨, 等.蛛网膜下腔出血合并脑室出血后继发吉兰-巴雷综合征1例[J].中国实用神经疾病杂志, 2018, 21(14):1615. |
[10] |
WU Q, LIU N, PAN C, et al.Guillain-Barré syndrome and cerebral hemorrhage:two cases and literature review[J].Eur Neurol, 2016, 76(3/4):182. |
[11] |
王学建, 汪志峰.脑动脉瘤术后合并吉兰-巴雷综合征一例[J].中国神经免疫学和神经病学杂志, 2018, 25(6):455. doi: 10.3969/j.issn.1006-2963.2018.06.017 |
[12] |
宁娜, 陈乃宏.神经节苷脂的生物学活性[J].生理科学进展, 2009, 40(1):24. |
[13] |
钟东, 唐文渊.神经节苷脂治疗急性脑外伤的神经电生理研究[J].中华创伤杂志, 1999, 6:26. |
[14] |
严志聪, 麦霭婷.单唾液酸四己糖神经节苷脂改善脑梗死患者神经功能缺损症状的疗效探讨[J].中外医疗, 2016, 35(14):46. |
[15] |
LATOV N, KOSKI CL, WALICKE PA.Guillain-Barre syndrome and parenteral gangliosides[J].Lancet, 1991, 338(8769):757. doi: 10.1016/0140-6736(91)91475-A |
[16] |
DÍEZ-TEJEDOR E, GutiéRREZ-RIVAS E, GIL-PERALTA A.Gangliosides and Guillain-Barré syndrome:the Spanish data[J].Neuroepidemiology, 1993, 12(5):251. doi: 10.1159/000110325 |
[17] |
RASCHETTI R, MAGGINI M, POPOLI P, et al.Gangliosides and Guillain-Barré syndrome[J].J Clin Epidemiol, 1995, 48(11):1399. doi: 10.1016/0895-4356(95)00557-9 |
[18] |
YUKI N.Guillain-Barré syndrome and anti-ganglioside antibodies:a clinician-scientist's journey[J].Proc Jpn Acad Ser B Phys Biol Sci, 2012, 88(7):299. doi: 10.2183/pjab.88.299 |
[19] |
GOODFELLOW JA, WILLISON HJ.Gangliosides and autoimmune peripheral nerve diseases[J].Prog Mol Biol Transl Sci, 2018, 156:355. doi: 10.1016/bs.pmbts.2017.12.010 |
[20] |
康健捷, 杨红军, 邓兵梅, 等.单唾液酸四己糖神经节苷脂相关性吉兰-巴雷综合征1例报告[J].药学与临床研究, 2018, 4:314. |
[21] |
王秀玲, 宋伟, 蔡其明.单唾液酸四己糖神经节苷脂钠注射液致新的/严重的不良反应分析[J].解放军药学学报, 2017, 33(3):282. |
[22] |
MOYANO AL, COMÍN R, LARDONE RD, et al.Validation of a rabbit model of neuropathy induced by immunization with gangliosides[J].J Neurol Sci, 2008, 272(1/2):110. |
[23] |
VAN DOORN PA, RUTS L, JACOBS BC.Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome[J].Lancet Neurol, 2008, 7(10):939. doi: 10.1016/S1474-4422(08)70215-1 |
[24] |
YANG B, LIAN Y, LIU Y, et al.A retrospective analysis of possible triggers of Guillain-Barre syndrome[J].J Neuroimmunol, 2016, 293:17. doi: 10.1016/j.jneuroim.2016.02.003 |
[25] |
XU S, PENG F, WANG YS, et al.Guillain-Barre syndrome complicated on postoperation on renal carcinoma and meningioma[J].Chin Med J (Engl), 2018, 131(9):1122. doi: 10.4103/0366-6999.230728 |
[26] |
KOC M, OZALP N, ZULFIKAROGLU B.Major surgery with Guillain-Barré syndrome:a case report[J].J Int Med Res, 2002, 30(6):601. doi: 10.1177/147323000203000609 |
[27] |
Donofrio PD.Guillain-Barré Syndrome[J].Continuum (Minneap Minn), 2017, 23(5):1295. |
[28] |
HUGHES RA, SWAN AV, VAN DOORN PA.Intravenous immunoglobulin for Guillain-Barré syndrome[J].Cochrane Database Syst Rev, 2014(9):CD002063. |
[29] |
RAPHAЁL JC, CHEVRET S, HUGHES RA, et al.Plasma exchange for Guillain-Barré syndrome[J].Cochrane Database Syst Rev, 2012(7):CD001798. |
[30] |
VERBOON C, VAN DOORN PA, JACOBS BC.TreatmentdilemmasinGuillain-Barré syndrome[J].J Neurol Neurosurg Psychiatry, 2017, 88(4):346. doi: 10.1136/jnnp-2016-314862 |
[31] |
WALGAARD C, LINGSMA HF, RUTS L, et al.Prediction of respiratory insufficiency in Guillain-Barré syndrome[J].Ann Neurol, 2010, 67(6):781. |
[32] |
KUWABARA S.Guillain-Barré syndrome:Epidemiology, pathophysiology and management[J].Drugs, 2004, 64(6):597. doi: 10.2165/00003495-200464060-00003 |
[33] |
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group, et al.Randomised trial of plasma exchange, intravenous immunoglobulin, andcombinedtreatments in Guillain-Barré syndrome[J].Lancet, 1997, 349(9047):225. doi: 10.1016/S0140-6736(96)09095-2 |
[34] |
KESICI S, TANYILDIZ M, YETIMAKMAN F, et al.A novel treatment strategy for severe Guillain-Barré syndrome:zipper method[J].J Child Neurol, 2019, 34(5):277. doi: 10.1177/0883073819826225 |
[35] |
HUGHES RA, VAN DOORN PA.Corticosteroids for Guillain-Barré syndrome[J].Cochrane Database Syst Rev, 2012(8):CD001446. |
[36] |
HARTUNG HP, SCHWENKE C, BITTER-SUERMANN D, et al.Guillain-Barré syndrome:activated complement components C3a and C5a in CSF[J].Neurology, 1987, 37(6):1006. doi: 10.1212/WNL.37.6.1006 |
[37] |
LIU S, DONG C, UBOGU EE.Immunotherapy of Guillain-Barré syndrome[J].Hum Vaccin Immunother, 2018, 14(11):2568. |
[38] |
MOTAMED-GORJI N, MATIN N, TABATABAIE O, et al.Biological drugs in Guillain-Barré syndrome:an update[J].Curr Neuropharmacol, 2017, 15(7):938. |